Conditions: Recent submissions
Now showing items 121-140 of 698
-
The alarms should no longer be ignored: A Survey of the Demand, Capacity and Provision of Adult Community Eating Disorder Services in England and Scotland before COVID-19
(2022-12)This national survey compared the demand and capacity of adult community eating disorder services (ACEDS) to NHSE Commissioning guidance. Results: Of 21 services approached in England and Scotland 13 responded (10.7 million ... -
What is Computational Psychiatry Good For?
(2022-09)It is rare in the field of biological psychiatry for hypotheses to be definitively refuted. Rather, topics of investigation drift into and out of fashion, often driven by the initial excitement of technological innovation, ... -
Creating a care pathway for patients with longstanding, complex eating disorders
(2022-08)Recovery rates for people with eating disorders are low; fewer than half recover and approximately 20% develop a longstanding eating disorder. Patients with longstanding eating disorders are often referred to as “SEED” ... -
The Needs and Experiences of Parents with Psychosis: A Qualitative Interview Study
(2022-09)Over a third of individuals diagnosed with a psychotic disorder are also a parent. The symptoms of psychosis and side effects of antipsychotic medication can impact on parents’ awareness of the needs of their children and, ... -
Empowering autistic academics
(2022-08)Drawing on her personal experience as an autistic scientist–practitioner, Eloise Stark explores how we can empower neurodivergent populations in academia. The disability employment gap is highly complex, and it would ... -
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ... -
Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities
(2022-08)There is growing evidence for the use of pharmacogenomics in psychotropic prescribing. People with intellectual disabilities are disproportionately prescribed psychotropics and are at risk of polypharmacy. There is an ... -
Screening for Autism Spectrum Condition Through Inner City Homeless Services in the Republic of Ireland
(2022-08)Homeless service users were screened for autism spectrum disorder through one of Ireland’s leading not for profit service providers. Keyworkers acted as proxy informants; their caseloads were screened using the DSM-5—Autistic ... -
A life more ordinary: A peer research method qualitative study of the Feeling Safe Programme for persecutory delusions
(2022-07)Background: The Feeling Safe Programme is a cognitive therapy developed to improve outcomes for individuals with persecutory delusions. It is theoretically driven, modular and personalised, with differences in ... -
Brain activity measured by functional brain imaging predicts breathlessness improvement during pulmonary rehabilitation
(2022-12)Background Chronic breathlessness in chronic obstructive pulmonary disease (COPD) is effectively treated with pulmonary rehabilitation. However, baseline patient characteristics predicting improvements in breathlessness ... -
A family perspective on parental psychosis: An interpretative phenomenological analysis study
(2022-11)Objectives: While one third of people with a psychotic disorder are a parent, there has been little research to date examining the consequences of this from a whole family perspective. This study investigates families ... -
Use and risk of side effects of antiresorptive medication in people with intellectual disabilities [version 1; peer review: awaiting peer review]
(2022-12)Background: Recent studies show that adults with intellectual disabilities (ID) have high incidence of major osteoporotic fracture, especially hip fracture. In those ≥ 50 years, women and men with ID have an approximately ... -
Statins in depression: a repurposed medical treatment can provide novel insights in mental health
(2022-08)Depression has a large burden, but the development of new drugs for its treatment has proved difficult. Progresses in neuroscience have highlighted several physiopathological pathways, notably inflammatory and metabolic ... -
Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review
(2022-08)The COVID-19 pandemic required mental health services around the world to adapt quickly to the new restrictions and regulations put in place to reduce the risk of transmission. As face-to-face contact became difficult, ... -
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents
(2022-05)Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal. Little is known however about how current pharmacotherapies act to modulate ... -
Can CBT-E be delivered in an online group format? A pilot study of the Body Image module in a child and adolescent eating disorder service
(2022-07)he increased prevalence of eating disorders during the COVID-19 pandemic has led to long waiting lists in child and adolescent services. A pilot study was conducted to evaluate the feasibility and acceptability of providing ... -
A narrative review of ablative neurosurgery in refractory mental disorders
(2022-07)Neurosurgery for mental disorder (NMD) is currently performed in the UK for cases of severe depressive disorder and obsessive–compulsive disorder refractory to treatment, under stringent regulations as set out under the ... -
Psychosocial markers of age at onset in bipolar disorder: a machine learning approach
(2022-07)Bipolar disorder is a chronic and severe mental health disorder. Early stratification of individuals into subgroups based on age at onset (AAO) has the potential to inform diagnosis and early intervention. Yet, the ... -
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ...